Transcatheter vs. surgical closure of atrial septal defects in adults by Rudzītis, Ainars et al.
INTRODUCTION
Atrial septal defect (ASD) in adults is the most common
congenital heart disease (GUCH) after bicuspid aortic
valve, accounting for 25–30% of all congenital heart defects
(CHDs) diagnosed in adulthood (Marelli et al., 2006; Lind-
sey and Hillis, 2007; Van der Linde et al., 2011).
Surgical ASD closure is an effective procedure with low
mortality (approximately 1%) in patients without significant
comorbidities and with excellent long-term results (normal
life expectancy and low long-term morbidity) when per-
formed early (patients < 25 years old and without pulmo-
nary arterial hypertension) (Murphy et al., 1990; Roos-Hes-
selink et al., 2003).
Transcatheter device closure has become the treatment of
choice for patients with amenable secundum ASD anatomy
(Warnes et al., 2008; Baumgartner et al., 2010; Akagi,
2015), providing similar efficacy and haemodynamic bene-
fits compared to surgery (Du et al., 2002; Rosas et al.,
2007; Kutty et al., 2011). Being significantly less invasive,
it allows to avoid problems associated with open heart sur-
gery (anaesthesia, thoracotomy, cardiopulmonary bypass,
etc.) and is also associated with fewer complications and
shorter hospital stay, especially in older adults (Du et al.,
2002; Rosas et al., 2007; Ooi et al., 2016).
Nevertheless, transcatheter device closure is associated with
specific complications and no known equivalent risk for
surgical patients. Device embolisation is the most common
complication (prevalence 0.55–0.62%), often requiring sur-
gical retrieval (Levi and Moore, 2004; Moore et al., 2013).
Another rare, but potentially fatal complication is erosion or
cardiac perforation (reported only with certain device
types), estimated to occur in 0.1% to 0.28% of all cases and
reported as late as eight years after deployment (Amin et
al., 2004; DiBardino et al., 2009; Moore et al., 2013; Rob-
erts et al., 2013). More rarely, device infection with subse-
quent endocarditis, nickel allergy, thrombus formation or
residual/recurrent defect following device closure can occur
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Percutaneous transcatheter device closure of secundum atrial septal defects (ASD) has now
largely replaced surgical closure in most centres. The aim of this study was to compare results of
transcatheter and surgical ASD closure in adults in Latvia during the years 2002–2014 and to
analyse long-term outcomes of transcatheter closure. We analysed data from 334 patients with
secundum ASD who underwent ASD closure in Pauls Stradiòð Clinical University Hospital. Pa-
tients were included into device or surgical closure groups. In the device group, three follow-ups
were made 1, 6, and 12 months after the procedure. No follow-up data were available for surgical
arm patients beyond their hospitalisation period. The mean age of patients was 45.3 ± 19.9 years
for the device group and 40.0 ± 16.9 years for the surgical group (p = 0.023). The mean
secundum ASD size in the device and surgical groups was 14.2 ± 5.6 mm and 28.7 ± 10.0 mm,
respectively (p < 0.001). No differences were observed regarding procedure success rates:
99.2% in the device group and 100% in the surgical group (p = 0.451). Periprocedural complica-
tions generally were more common in the surgical closure group. The study results show a suc-
cessful introduction of the percutaneous ASD closure method in Latvia with good early and late
outcomes and without significant differences in procedure success rate compared to surgical clo-
sure.
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(DiBardino et al., 2009; Moore et al., 2013). As with surgi-
cal closure, ASD device closure after the age of 40 years
appears not to affect the frequency of arrhythmia develop-
ment during follow-up (Attie et al., 2001; Humenberger et
al., 2011). After device closure, regular follow-up is recom-
mended during the first 1–2 years and then periodically
thereafter (Warnes et al., 2008; Baumgartner et al., 2010).
The aim of this study was to evaluate safety, efficacy, im-
mediate- and short-term results of ostium secundum tran-
scatheter device closure and to compare the results of iso-
lated secundum ASD closure by transcatheter vs. surgical
method in adults treated in the Latvian Centre of Cardiol-
ogy during the period 2002–2014. Further, we analysed the
long-term results of transcatheter closure in terms of safety
and late complications — erosions, embolisations and ar-
rhythmias.
MATERIALS AND METHODS
Between June 2002 and December 2014 (12.6 years), 259
adult patients (18 years old) with secundum ASD under-
went percutaneous device closure in Latvian Centre of Car-
diology, Pauls Stradiòð Clinical University Hospital
(PSCUH). Concurrently, a national registry for ASD
transcatheter device closure was created. We also retrospec-
tively collected data on 75 consecutive patients with
secundum ASD who underwent surgical closure in PSCUH
in the time period from January 2002 until December 2012
(11 years). The study was approved by the PSCUH Ethics
Committee.
Patients were enrolled into device or surgical closure
groups. Inclusion criteria for both groups included: 1) the
presence of a secundum ASD (diameter of  38 mm for de-
vice group; no limit for surgery group); 2) a left-to-right
shunt with a Qp/Qs ratio of  1.5:1 or the presence of RV
volume overload. Additional inclusion criteria for the de-
vice group was the presence of an > 5 mm rim of surround-
ing atrial tissue to the coronary sinus, atrioventricular valves
and right upper pulmonary vein as measured by echocardio-
graphy. Exclusion criteria for both groups were: 1) ostium
primum and sinus venosus ASDs, including partial anoma-
lous pulmonary venous drainage; 2) patients with other as-
sociated CHDs (e.g., ventricular septal defect, tetralogy of
Fallot) or cardiac pathologies (e.g., valvular heart disease,
coronary artery disease) requiring surgical or percutaneous
repair. The final decision for patient inclusion in either sur-
gical or device group was made by an interdisciplinary heart
team consisting of cardiologists and cardiac surgeons.
Before the procedure, all patients had undergone transtho-
racic (TTE) or transesophageal (TEE) echocardiography
and electrocardiography (ECG).
Secundum ASD device closure was performed under local
anaesthesia by puncturing and catheterising the right femo-
ral vein. Stretched (stop-flow) diameter of ASD was meas-
ured using a sizing balloon. Two types of closure devices
were used in this study: AMPLATZER septal occluder
(ASO; St. Jude Medical Inc., St. Paul, Minnesota, U.S.) and
GORE HELEX septal occluder (HSO; W.L. Gore and As-
sociates, Flagstaff, Arizona, U.S.). The choice of the device
used depended on the size and anatomy of the ASD. The
size of the device was 2 mm larger than stretched diameter
of ASD in case of deployment of ASO and twice stop-flow
diameter in case of HSO.
All procedures were performed with continuous fluoro-
scopic and TEE monitoring. 100 IU/kg heparin i/v was ad-
ministered to achieve an activated clotting time > 200 sec-
onds at the time of device deployment along with 1 g
cefazolin intravenously. Aspirin 100 mg was initiated 24 h
before closure and continued for six months after.
All surgical defect closures were performed under general
anaesthesia with cardiopulmonary bypass using median
sternotomy and right atriotomy to gain access to the right
atrium. The defect was closed either by direct suture or by
autologous pericardial patch.
A TTE with colour Doppler was used for patients after sur-
gical closure and before discharge for assessment of any re-
sidual shunts. For patients who had device closure, a TEE
with colour Doppler was done immediately after the proce-
dure. Patients were considered to have a successful ASD
closure if there was a complete closure of the defect or no
significant residual shunts (colour jet width  2 mm). In ad-
dition, a chest x-ray, an ECG and a physical examination
was conducted in both groups within 24 h after the proce-
dure.
Patients in the device closure group underwent physical ex-
amination, an ECG and a TTE with colour Doppler at one,
six and twelve months after the procedure. We did not have
any follow-up data on surgical arm patients beyond their
hospitalisation period.
Statistical methods. The Kolmogorov–Smirnov test was
used to assess normality of data. Comparisons of continu-
ous data measured at baseline for the study groups were
analysed using the Welch’s t-test, assuming the possibility
of unequal variances. The Mann-Whitney U test was used
to compare days of hospitalisation, right ventricular systolic
pressure (RVSP), right atrial (RA) volume index, ASD
transcatheter device closure procedure time and fluoroscopy
time and length of hospital stay between the two groups, be-
cause these data were not normally distributed. The
Wilcoxon signed-rank test was used to compare two paired
samples of nonparametric data. For categorical variables,
we used cross-tabulations and the Pearson’s chi-squared
test, or Fisher’s exact test for 2 × 2 tables when one or more
of the cells had an expected frequency of less than 5. IBM
SPSS Statistics 21.0 and Microsoft Office Excel 2011 was
used for data analysis. Data are reported as mean ± SD or
median and interquartile range (IQR) as appropriate. A P
value of < 0.05 was considered statistically significant.
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RESULTS
Baseline data. A total of 334 patients were enrolled in the
study: 259 (77.5%) patients with device closure and 75
(22.5%) patients with surgical closure satisfied the inclu-
sion/exclusion criteria and were included as subjects in each
arm of the study. Patient baseline characteristics and proce-
dure-related data in both groups are listed in Table 1.
The patients in device group were older than those in surgi-
cal group; mean age was 45.3 ± 19.9 and 40.0 ± 16.9 years,
respectively, p = 0.023. In both groups, most of the patients
were women (77.2% of all patients in the device group and
61.3% in the surgical group). There were no significant dif-
ferences in mean body mass index between the two groups.
Arterial hypertension and recurring headaches were more
common in the device group and previously diagnosed con-
gestive heart failure was observed more often in the surgical
group, although there was no difference in mean left ven-
tricular ejection fraction between the groups. Also, there
were no significant differences with respect to presence of
other previous/ongoing medical conditions between the pa-
tients in the two study arms.
Atrial septal aneurysm was more common in device closure
group patients, p = 0.026. Signs of right heart volume over-
load were more frequently observed in the surgical closure
group: dilatation of right atrium (RA) and right ventricle
(RV) was present in 86.7% and 84.0% of the surgical group
patients, respectively, compared with 48.3% and 51.4% of
patients in the device group, p < 0.001 in both cases. How-
ever, right heart dilatation was not significantly more pro-
nounced in the surgical group — mean RV diameter was
46.5 ± 8.0 mm compared to 42.5 ± 8.9 mm in the device
group, p = 0.789. Nevertheless, surgical group patients had
significantly higher median RVSP (45.0 mmHg, IQR
37.5–60.0 mmHg) and median tricuspid regurgitation (TR)
grade (grade 2), compared to device group median RVSP
(37.0 mmHg, IQR 30.0–45.0 mmHg) and TR grade (grade
1), respectively. These findings could be explained by the
significantly larger defects in the surgical group (28.7 ±
10.0 mm) than in the device group (14.2 ± 5.6 mm), p <
0.001.
Immediate- and short-term results. In the device closure
group most (n = 231, 89.2%) patients underwent closure
with ASO, 28 patients (10.8%) had ASD closed with HSO.
In one case there was a change from HSO to ASO due to
the problems with the positioning of the device; due to a de-
ficient antero-superior (aortic) rim, the HSO was prolapsing
to the right atrium creating a significant residual shunt.
Generally, ASO was used for closure of significantly larger
(p < 0.001) ASDs (primary secundum ASD size on TEE —
14.8 ± 5.6 mm), than HSO (ASD size — 9.1 ± 2.0 mm), al-
though the median diameter of HSO was larger than that of
ASO because of the technical properties of this device: 25
mm (IQR 20.0–28.75 mm) and 19.0 mm (IQR 15–24 mm),
respectively, p < 0.001. The comparison of immediate clo-
sure results, procedure related data, intra- and peri-
procedural complications and length of hospital stay be-
tween the both study arms is demonstrated in Table 2.
In the surgical closure group, all (100%) patients had a suc-
cessful operation with only three patients (4%) having in-
significant residual shunt postoperatively, whereas success
rate in the device group was 99.2%. with two patients
(0.8%) having significant residual shunt and 134 patients
(51.7%) having insignificant residual shunt.
Mean stretched ASD diameter in the device group was 17.6
± 5.9 mm. Median percutaneous procedure duration was 45
minutes (IQR 35–60 minutes), median fluoroscopy time
was 8.1 minutes (IQR 5.4–12.2 minutes). During surgical
T a b l e 1
COMPARISON OF DEMOGRAPHIC AND BASELINE CLINICAL







Age, years (range) 45.3 ± 19.9 (18-79) 40.0 ± 16.9 (18-76) 0.023
Females 200 (77.2%) 46 (61.3%) 0.06
BMI, kg/m2 24.9 ± 5 .3 24.8 ± 5.3 0.921
Medical history
Arterial hypertension 80 (30.9%) 6 (8.0%) < 0.001
Diabetes mellitus 7 (2.7%) 3 (4.0%) 0.699
Myocardial infarction 4 (1.6%) 3 (4.0%) 0.193
Congestive heart failure 158 (61.0%) 67 (89.3%) < 0.001
Supraventricular
tachyarrhythmia
48 (18.6%) 12 (16.0%) 0.545
Previous stroke/TIA 12 (4.6%) 0 (0.0%) 0.075
Headaches 26 (10.0%) 2 (2.7%) 0.021
Palpitations 56 (21.6%) 15 (20.0%) 0.762
Vertigo 23 (8.9%) 5 (6.7%) 0.359
Echocardiographic findings
LV ejection fraction, % 64.3 ± 6.7 62.7 ± 9.6 0.208
Atrial septal aneurysm 44 (17.0%) 5 (6.7%) 0.026
Number of ASD de-
fects:
0.817
One 229 (88.4%) 68 (90.7%)
Two 24 (9.3%) 6 (8.0%)
Three and more 6 (2.3%) 1 (1.3%)
Primary secundum ASD
size on TEE, mm
14.2 ± 5.6 28.7 ± 10.0 < 0.001
RA dilatation on TTE
(visual assessment)
125 (48.3 %) 65 (86.7%) < 0.001
RV dilatation on TTE
(visual assessment)
134 (51.7%) 63 (84.0%) < 0.001
RV basal diameter on
TTE, mm
42.5 ± 8.9 46.5 ± 8.0 0.789
RVSP, mmHg, median
(IQR)
37.0 (30.0–45.0) 45.0 (37.5–60.0) < 0.001
TR grade, median (IQR) 1 (1–2) 2 (1–2) 0.008
ASD, atrial septal defect; BMI, body mass index; IQR, interquartile range;
LV, left ventricle; RA, right atrium; RV, right ventricle; RVSP, right ven-
tricular systolic pressure; TEE, transesophageal echocardiography; TIA,
transient ischemic attack; TR, tricuspid regurgitation; TTE, transthoracic
echocardiography.
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ASD closure, mean cardiopulmonary bypass time was 61.9
± 32.3 minutes and reperfusion time — 21.9 ± 9.7 minutes.
Median length of hospital stay was significantly longer (p <
0.001) in the surgery group (13 days, IQR 11–16 days), in
comparison with the device group (2 days, IQR 2–3 days).
While no intraprocedural complications were observed in
the surgery group, there was one case of device embolisa-
tion immediately after the disconnection of the delivery
cable in the device group. The device was retrieved percuta-
neously by snaring it from the descending aorta by trans-
femoral arterial approach without any further complications
and subsequent ASD closure was successful. Postprocedural
new-onset cardiac arrhythmias (most commonly- atrial fib-
rillation) more often occurred in the device group, although
the difference did not achieve statistical significance (7
(2.7%) and 1 (1.3%), respectively, p = 0.277)
In general, surgical arm patients more often had periproce-
dural complications, even though statistical significance
was attained only regarding pericardial effusion rate, where
nearly a third (29.3%) of surgical group patients developed
this complication (although in most cases the effusion was
clinically insignificant), compared to 6.2% of patients in the
device group, p < 0.001. Four surgical group patients re-
quired reoperation: one patient developed cardiac tampon-
ade, another patient developed clinically significant bleed-
ing and one patient developed mediastinitis with following
clinical deterioration and death. In one case the cause of
reoperation is unknown.
Follow-up. A total of 217 (83.8%) patients in the device
group completed one-month follow-up, 146 (56.4%) pa-
tients had six-month follow-up and 145 (56.0%) patients
had their evaluation completed at twelve-month follow-up.
119 (45.9%) patients were followed-up for more than 12
months. Median follow-up was 12 months. Total follow-up
was 465 person-years. Table 3 demonstrates device group
follow-up data.
Comparing data in the device group at baseline and at 30-
day follow-up, there was a significant reduction in RV di-
ameter from 42.5 ± 8.9 mmHg to 34.0 ± 7.7 mmHg, respec-
tively (p = 0.009); median RVSP also decreased signifi-
cantly, from 45 mmHg to 34 mmHg, respectively (p <
0.001).
No further significant changes (p = 0.932) were observed in
mean RV diameter at 12-month follow-up when compared
to 30-day follow-up; nevertheless, further reduction in me-
T a b l e 2
COMPARISON OF IMMEDIATE CLOSURE RESULTS, PROCEDURE
RELATED DATA, INTRA- AND PERIPROCEDURAL COMPLICA-




patients (n = 75)
p value
Successful procedures 257 (99.2%) 75 (100%) 0.451
Insignificant residual shunt 134 (51.7%) 3 (4.0%) < 0.001
Significant residual shunt 2 (0.8%) 0
Stretched ASD diameter, mm 17.6 ± 5.9 N/A -
Procedure time, minutes,
median (IQR)
45 (35-60) N/A -
Fluoroscopy time, minutes,
median (IQR)
8.1 (5.4-12.2) N/A -
CPB time, minutes N/A 61.9±32.3 -
Reperfusion time, minutes N/A 21.9±9.7 -
Length of hospital stay, days,
median (IQR)
2 (2–3) 13 (11–16) < 0.001
Intraprocedural complications 1 (0.4 %) 0 0.59
Device embolization 1 (0.4 %) N/A -
Periprocedural complications
Reoperation N/A 4 (5.3%) -
Stroke/TIA 0 2 (2.7%) 0.05
New-onset cardiac
arrhythmias
7 (2.7%) 1 (1.3%) 0.277
Pericardial effusion 16 (6.2%) 22 (29.3%) < 0.001
Death 0 1 (1.3%) 0.225
ASD, atrial septal defect; CPB, cardiopulmonary bypass; IQR, interquartile
range; TIA, transient ischemic attack. N/A = not available/applicable
T a b l e 3
FOLLOW-UP DATA FOR THE DEVICE CLOSURE GROUP
Parameter Value
Follow-up time, months; median (IQR) 12 (6–36)
Total follow-up time, person-years 465
Number of patients completed
30-day follow-up 217 (83.8%)
6-month follow-up 146 (56.4%)
12-month follow-up 145 (56.0%)
RV diameter on TTE, mm
At 30-day follow-up 34.0±7.7
At 6-month follow-up 34.4±7.6
At 12-month follow-up 34.2±7.3
RV systolic pressure, mmHg, median (IQR)
At 30-day follow-up 34 (29-38)
At 6-month follow-up 30 (25-37)
At 12-month follow-up 30 (25-35)
Significant residual shunt  30 days 2 (0.9%*)
Significant residual shunt > 30 days (events per 100
person-years)
1 (0.2)
Insignificant residual shunt  30 days 59 (27.2%*)
Insignificant residual shunt > 30 days (events per 100
person-years)
32 (6.9)
Cerebrovascular events  30 days 0
Cerebrovascular events > 30 days (events per 100
person-years)
0
Cardiac arrhythmias  30 days 20 (9.2%*)
Cardiac arrhythmias > 30 days (events per 100
person-years)
13 (2.8)
Major complications during follow-up period (events per
100 person-years)
1 (0.2)
Device embolisation during follow-up period (events per
100 person-years)
0
RV, right ventricle; TTE, transthoracic echocardiography; * percentage
calculated from patients who completed respective follow-up
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dian RVSP was seen, from 34 mmHg to 30 mmHg, respec-
tively, p = 0.001. In two cases, there was a significant resid-
ual shunting present at 30-day follow-up: one patient
underwent successful device closure two years later; the
other patient’s shunt had decreased at six-month follow-up
and was classified as insignificant. Of the 217 patients who
completed 30-day follow-up, 59 patients (27.2%) had
nonsignificant residual shunt and 20 patients (9.2%) had
cardiac arrhythmias (atrial flutter or fibrillation). Of the 146
patients who were followed up at least 6 months, non-
significant residual shunt was observed in 32 patients
(21.9%) and cardiac arrhythmias in 13 patients (8.9%).
There were no known cerebrovascular events or device ero-
sion/embolisation during follow-up period, although one
patient required explantation of HSO and subsequent surgi-
cal closure six years after initial device closure due to
symptoms caused by significant left-to-right shunt through
patent foramen ovale (PFO). The shunt resulted from the
device stretching the concurrent PFO. Postoperative echo-
cardiography confirmed complete closure.
Changes in secundum ASD closure technique. Analysing
ASD closure rate per year, there was a trend towards in-
crease in number of procedures performed percutaneously
since the introduction of this method in June 2002, with
concurrent decrease in number of surgical closures (Fig. 1).
We were not able to obtain any data regarding surgical ASD
closure after 2012.
DISCUSSION
Surgery, once being the only available method of CHD cor-
rection and for a long time being the gold standard of treat-
ment for such defects, nowadays is being partially replaced
by percutaneous transcatheter treatment, which has become
the method of choice for certain CHDs like secundum ASD,
which in most cases is amenable to percutaneous closure.
Nevertheless, there are several conditions that still require
surgery (large defect, deficient rim of surrounding atrial tis-
sue, etc.).
The present study reports the status of secundum ASD
percutaneous management in adults in Latvia over a time
period of more than 10 years. Study results reflect the
changes in management of secundum ASDs. Since the in-
troduction of percutaneous transcatheter treatment in mid-
2002, there was an increasing number of patients who un-
derwent device closure, with simultaneous decrease in num-
ber of surgical closures, resulting in ratio of device to surgi-
cal patients (during 2002–2012 period) of approximately
3 : 1. Although there was a noticeable drop in number of
transcatheter procedures performed after 2009, these
changes are linked to decrease in prevalence of patients who
(before the availability of percutaneous closure) had refused
surgery due to its invasive nature, and also to our country’s
economy status, which influenced the maximum number of
these procedures per year.
Patients who underwent surgical closure generally had a
more serious baseline condition; they had larger ASDs and,
therefore more frequently had signs of volume overload in
the right heart and pulmonary vasculature, resulting in in-
creased frequency of symptoms, with these changes occur-
ring at a younger age than in patients in the device group.
The study results confirm that device closure is a safe and
effective alternative to surgery when appropriate, as 99.2%
of device closures were successful and there was no signifi-
cant difference in procedure success rate compared to surgi-
cal closure, even though insignificant postprocedural resid-
ual shunt was observed in  50% of all device closure cases.
However, the shunt was detected in only 27% of patients
who completed 30-day follow-up due to device endothelia-
lisation and subsequent spontaneous closure. Device
embolisation was observed in 0.4% of all cases, which is
similar to previously published data. Also, device closure
was associated with fewer periprocedural complications and
resulted in a shorter hospitalisation period.
ASD closure had a beneficial influence on patients’ hemo-
dynamic status. After one-month volume overload both in
right heart and pulmonary vascular bed had significantly de-
creased, when compared to the baseline.
Regarding long-term safety, there were no life-threatening
complications after device implantation. No cerebrovascular
events or device erosion/embolisation occurred at any time
during the follow-up period, even though there was one late
complication requiring surgical intervention.
Study limitations include its retrospective design and rela-
tively large proportion of patients lost to follow-up: 16.2%,
43.6%, and 44% of patients in the device group were lost
to follow-up at one-month, six-months and one-year, re-
spectively.This was possibly due to the retrospective long-
term design of the study, meaning that a number of pa-
tients underwent follow-up at their place of residence, not
PSCUH. This was due to the retrospective long-term design
Fig. 1. Patient distribution by year and by procedure type. * – no data.
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of the study, where some patients were followed-up at their
place of residence, and some patients had emigrating. We
included in the study analysis only well-documented data
from our centre. However, no serious adverse events or
death due to device failure were reported to the study au-
thors.
CONCLUSIONS
Our results reflect a successful introduction of the mini-
mally invasive ASD closure method in Latvia with good
early and late outcomes and with fewer periprocedural com-
plications and shorter hospitalisation period when compared
to surgical closure. However, as currently most commonly
used transcatheter devices are not biodegradable and the
method is relatively new, further studies are needed to eval-
uate long-term safety of these devices.
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TRANSKATETRÂLA UN ÍIRURÌISKA ÂTRIJU STARPSIENAS DEFEKTU SLÇGÐANA PIEAUGUÐAJIEM
Perkutâna transkatetrâla âtriju starpsienas secundum tipa defektu (ASD) slçgðana aizvieto íirurìisku slçgðanu vairumâ centru. Pçtîjuma
mçríis bija salîdzinât transkatetrâlas un íirurìiskas ASD slçgðanas rezultâtus pieauguðajiem Latvijâ laikâ no 2002. lîdz 2014. gadam un
analizçt ilgtermiòa rezultâtus transkatetrâlas slçgðanas grupâ. Tika analizçti 334 pacientu dati, kuriem P. Stradiòa Klîniskajâ universitâtes
slimnîcâ veikta ASD slçgðana. Pacienti tika iedalîti transkatetrâlas un íirurìiskas slçgðanas grupâs. Transkatetrâlas slçgðanas grupai tika
veikta apsekoðana pçc 1, 6 un 12 mçneðiem. Pacientu vidçjais vecums bija 45,3 ± 19,9 gadi transkatetrâlas un 40,0 ± 16,9 gadi íirurìiskas
slçgðanas grupâs (P = 0.023). Vidçjais secundum tipa ASD izmçrs transkatetrâlas un íirurìiskas slçgðanas grupâs bija attiecîgi 14,2 ± 5,6
mm un 28,7 ± 10,0 mm (p < 0,001). Netika novçrotas bûtiskas atðíirîbas procedûru sekmîgâ iznâkumâ — tie bija 99,2% transkatetrâlas
slçgðanas un 100% íirurìiskas slçgðanas grupâs (p = 0,451). Periprocedurâlas komplikâcijas kopumâ bija bieþâk sastopamas íirurìiskas
slçgðanas grupâ. Pçtîjums parâda veiksmîgu ASD transkatetrâlas slçgðanas metodes pielietojumu Latvijâ, uzrâdot labus agrînus un vçlînus
iznâkumus un neuzrâdot bûtiskas atðíirîbas procedûru sekmîgâ norisç, salîdzinot ar íirurìisku ASD slçgðanu.
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